Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

about

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

P2860

Q50047476-7A1BC9D2-4F3D-4CD3-BFE6-E8669FF4E690

P2860

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

Item

http://www.wikidata.org/entity/Q47965108

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

@en

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

@nl

type

Item

label

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

@en

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

@nl

prefLabel

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

@en

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

@nl

P1476

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

@en

P2093

Kiran Naqvi

http://www.w3.org/2001/XMLSchema#string

P2860

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

The Bcl-2 apoptotic switch in cancer development and therapy

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

P304

863-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1366852

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Farhad Ravandi

Marina Konopleva

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28799432

http://www.w3.org/2001/XMLSchema#string

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

about

P2860

P2860

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698